Table of Contents Author Guidelines Submit a Manuscript
Neurology Research International
Volume 2016 (2016), Article ID 1952561, 9 pages
http://dx.doi.org/10.1155/2016/1952561
Research Article

Protective Effect of PPARγ Agonists on Cerebellar Tissues Oxidative Damage in Hypothyroid Rats

1Student Research Committee, Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2Neurocognitive Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
3Neurogenic Inflammation Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
4Department of Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Received 23 August 2016; Revised 6 November 2016; Accepted 30 November 2016

Academic Editor: Changiz Geula

Copyright © 2016 Yousef Baghcheghi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Halliwell and J. M. Gutteridge, Free Radicals in Biology and Medicine, Oxford University Press, Oxford, UK, 2001.
  2. P. Venditti and S. Di Meo, “Thyroid hormone-induced oxidative stress,” Cellular and Molecular Life Sciences, vol. 63, no. 4, pp. 414–434, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Mogulkoc, A. K. Baltaci, L. Aydin, E. Oztekin, and A. Sivrikaya, “The effect of thyroxine administration on lipid peroxidation in different tissues of rats with hypothyroidism,” Acta Physiologica Hungarica, vol. 92, no. 1, pp. 39–46, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. S. O. Rahaman, S. Ghosh, K. P. Mohanakumar, S. Das, and P. Kumar Sarkar, “Hypothyroidism in the developing rat brain is associated with marked oxidative stress and aberrant intraneuronal accumulation of neurofilaments,” Neuroscience Research, vol. 40, no. 3, pp. 273–279, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. C. C. Thompson and G. B. Potter, “Thyroid hormone action in neural development,” Cerebral Cortex, vol. 10, no. 10, pp. 939–945, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. J. H. Oppenheimer and H. L. Schwartz, “Molecular basis of thyroid hormone-dependent brain development,” Endocrine Reviews, vol. 18, no. 4, pp. 462–475, 1997. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Martinez, P. Del Hoyo, M. A. Martin, J. Arenas, A. Perez-Castillo, and A. Santos, “Thyroid hormone regulates oxidative phosphorylation in the cerebral cortex and striatum of neonatal rats,” Journal of Neurochemistry, vol. 78, no. 5, pp. 1054–1063, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. S. S. Katyare, C. S. Bangur, and J. L. Howland, “Is respiratory activity in the brain mitochondria responsive to thyroid hormone action?: a critical re-evaluation,” Biochemical Journal, vol. 302, no. 3, pp. 857–860, 1994. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Cattani, P. B. Goulart, V. L. D. L. O. Cavalli et al., “Congenital hypothyroidism alters the oxidative status, enzyme activities and morphological parameters in the hippocampus of developing rats,” Molecular and Cellular Endocrinology, vol. 375, no. 1-2, pp. 14–26, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Abedelhaffez and A. Hassan, “Brain derived neurotrophic factor and oxidative stress index in pups with developmental hypothyroidism: neuroprotective effects of selenium,” Acta Physiologica Hungarica, vol. 100, no. 2, pp. 197–210, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Bhanja and G. B. N. Chainy, “PTU-induced hypothyroidism modulates antioxidant defence status in the developing cerebellum,” International Journal of Developmental Neuroscience, vol. 28, no. 3, pp. 251–262, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Jiang, A. T. Ting, and B. Seed, “PPAR-γ agonists inhibit production of monocyte inflammatory cytokines,” Nature, vol. 391, no. 6662, pp. 82–86, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. G. E. Landreth and M. T. Heneka, “Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease,” Neurobiology of Aging, vol. 22, no. 6, pp. 937–944, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Dehmer, M. T. Heneka, M. Sastre, J. Dichgans, and J. B. Schulz, “Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with IκBα induction and block of NFκB and iNOS activation,” Journal of Neurochemistry, vol. 88, no. 2, pp. 494–501, 2004. View at Google Scholar · View at Scopus
  16. J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer, “An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ),” The Journal of Biological Chemistry, vol. 270, no. 22, pp. 12953–12956, 1995. View at Publisher · View at Google Scholar · View at Scopus
  17. T. M. Willson, J. E. Cobb, D. J. Cowan et al., “The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones,” Journal of Medicinal Chemistry, vol. 39, no. 3, pp. 665–668, 1996. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Kielian and P. D. Drew, “Effects of peroxisome proliferator-activated receptor-γ agonists on central nervous system inflammation,” Journal of Neuroscience Research, vol. 71, no. 3, pp. 315–325, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. X. Yu, X.-G. Shao, H. Sun et al., “Activation of cerebral peroxisome proliferator-activated receptors gamma exerts neuroprotection by inhibiting oxidative stress following pilocarpine-induced status epilepticus,” Brain Research, vol. 1200, pp. 146–158, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Ding, M. Fu, Q. Qin et al., “Cardiac peroxisome proliferator-activated receptor δ is essential in protecting cardiomyocytes from oxidative damage,” Cardiovascular Research, vol. 76, no. 2, pp. 269–279, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. S. S. Chung, M. Kim, B.-S. Youn et al., “Glutathione peroxidase 3 mediates the antioxidant effect of peroxisome proliferator-activated receptor γ in human skeletal muscle cells,” Molecular and Cellular Biology, vol. 29, no. 1, pp. 20–30, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Ishii, K. Itoh, E. Ruiz et al., “Role of Nrf2 in the regulation of CD36 and stress protein expression in murine macrophages: activation by oxidatively modified LDL and 4-hydroxynonenal,” Circulation Research, vol. 94, no. 5, pp. 609–616, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Nagy, P. Tontonoz, J. G. A. Alvarez, H. Chen, and R. M. Evans, “Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ,” Cell, vol. 93, no. 2, pp. 229–240, 1998. View at Publisher · View at Google Scholar · View at Scopus
  24. J. M. Kleinhenz, D. J. Kleinhenz, S. You et al., “Disruption of endothelial peroxisome proliferator-activated receptor-γ reduces vascular nitric oxide production,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 297, no. 5, pp. H1647–H1654, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. X. Wang, Z. Wang, J. Z. Liu et al., “Double antioxidant activities of rosiglitazone against high glucose-induced oxidative stress in hepatocyte,” Toxicology in Vitro, vol. 25, no. 4, pp. 839–847, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. A. A. Herzlich, X. Ding, D. Shen, R. J. Ross, J. Tuo, and C. Chan, “Peroxisome proliferator-activated receptor expression in murine models and humans with age-related macular degeneration,” The Open Biology Journal, vol. 2, no. 1, pp. 141–148, 2009. View at Publisher · View at Google Scholar
  27. A. Pautz, J. Art, S. Hahn, S. Nowag, C. Voss, and H. Kleinert, “Regulation of the expression of inducible nitric oxide synthase,” Nitric Oxide - Biology and Chemistry, vol. 23, no. 2, pp. 75–93, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Galli, T. Mello, and S. Polvani, “Peroxisome proliferator-activated receptor and retinoic X receptor in alcoholic liver disease,” PPAR Research, vol. 2009, Article ID 748174, 11 pages, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Shimazu, I. Inoue, N. Araki et al., “A peroxisome proliferator-activated receptor-γ agonist reduces infarct size in transient but not in permanent ischemia,” Stroke, vol. 36, no. 2, pp. 353–359, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Khandoudi, P. Delerive, I. Berrebi-Bertrand, R. E. Buckingham, B. Staels, and A. Bril, “Rosiglitazone, a peroxisome proliferator-activated receptor-γ, inhibits the Jun NH2-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury,” Diabetes, vol. 51, no. 5, pp. 1507–1514, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Okada, S. F. Yan, and D. J. Pinsky, “Peroxisome proliferator-activated receptor-γ (PPAR-γ) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets,” The FASEB Journal, vol. 16, no. 14, pp. 1861–1868, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. N. S. Wayman, Y. Hattori, M. C. Mcdonald et al., “Ligands of the peroxisome proliferator-activated receptors (PPAR-γ and PPAR-α) reduce myocardial infarct size,” FASEB Journal, vol. 16, no. 9, pp. 1027–1040, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. H.-C. Yang, S. Deleuze, Y. Zuo, S. A. Potthoff, L.-J. Ma, and A. B. Fogo, “The PPARγ agonist pioglitazone ameliorates aging-related progressive renal injury,” Journal of the American Society of Nephrology, vol. 20, no. 11, pp. 2380–2388, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Collino, M. Aragno, R. Mastrocola et al., “Modulation of the oxidative stress and inflammatory response by PPAR-γ agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion,” European Journal of Pharmacology, vol. 530, no. 1-2, pp. 70–80, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Sundararajan, J. L. Gamboa, N. A. Victor, E. W. Wanderi, W. D. Lust, and G. E. Landreth, “Peroxisome proliferator-activated receptor-γ ligands reduce inflammation and infarction size in transient focal ischemia,” Neuroscience, vol. 130, no. 3, pp. 685–696, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Collino, N. S. A. Patel, and C. Thiemermann, “Review: PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury,” Therapeutic Advances in Cardiovascular Disease, vol. 2, no. 3, pp. 179–197, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Choopankareh, F. Vafaee, M. N. Shafei et al., “Effects of melatonin and theanine administration on pentylenetetrazole-induced seizures and brain tissue oxidative damage in ovariectomized rats,” Turkish Journal of Medical Sciences, vol. 45, no. 4, pp. 842–849, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Anaeigoudari, M. N. Shafei, M. Soukhtanloo et al., “Lipopolysaccharide-induced memory impairment in rats is preventable using 7-nitroindazole,” Arquivos de Neuro-Psiquiatria, vol. 73, no. 9, pp. 784–790, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Madesh and K. A. Balasubramanian, “Microtiter plate assay for superoxide dismutase using MTT reduction by superoxide,” Indian Journal of Biochemistry & Biophysics, vol. 35, no. 3, pp. 184–188, 1998. View at Google Scholar · View at Scopus
  40. A. Anaeigoudari, M. Soukhtanloo, M. N. Shafei et al., “Neuronal nitric oxide synthase has a role in the detrimental effects of lipopolysaccharide on spatial memory and synaptic plasticity in rats,” Pharmacological Reports, vol. 68, no. 2, pp. 243–249, 2016. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Hosseini, S. S. Dastghaib, H. Rafatpanah, M. A.-R. Hadjzadeh, H. Nahrevanian, and I. Farrokhi, “Nitric oxide contributes to learning and memory deficits observed in hypothyroid rats during neonatal and juvenile growth,” Clinics, vol. 65, no. 11, pp. 1175–1181, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Hosseini, F. Harandizadeh, S. Niazmand, M. Soukhtanloo, A. Faizpour, and M. Ghasemabady, “The role for nitric oxide on the effects of hydroalcoholic extract of Achillea wilhelmsii on seizure,” Avicenna Journal of Phytomedicine, vol. 4, pp. 251–259, 2014. View at Google Scholar
  43. O. Broedel, M. Eravci, S. Fuxius et al., “Effects of hyper- and hypothyroidism on thyroid hormone concentrations in regions of the rat brain,” American Journal of Physiology—Endocrinology and Metabolism, vol. 285, no. 3, pp. E470–E480, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. E. Kebebew, M. Peng, E. Reiff et al., “A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer,” Surgery, vol. 140, no. 6, pp. 960–967, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Tepmongkol, S. Keelawat, S. Honsawek, and P. Ruangvejvorachai, “Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma,” Thyroid, vol. 18, no. 7, pp. 697–704, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Jena, G. B. N. Chainy, and J. Dandapat, “Hypothyroidism modulates renal antioxidant gene expression during postnatal development and maturation in rat,” General and Comparative Endocrinology, vol. 178, no. 1, pp. 8–18, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. D. K. Sahoo, A. Roy, S. Bhanja, and G. B. N. Chainy, “Hypothyroidism impairs antioxidant defence system and testicular physiology during development and maturation,” General and Comparative Endocrinology, vol. 156, no. 1, pp. 63–70, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Chattopadhyay, D. K. Sahoo, U. Subudhi, and G. B. N. Chainy, “Differential expression profiles of antioxidant enzymes and glutathione redox status in hyperthyroid rats: a temporal analysis,” Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology, vol. 146, no. 3, pp. 383–391, 2007. View at Publisher · View at Google Scholar · View at Scopus
  49. K. Das and G. B. N. Chainy, “Thyroid Hormone influences antioxidant defense system in adult rat brain,” Neurochemical Research, vol. 29, no. 9, pp. 1755–1766, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Bhanja and S. Jena, “Modulation of antioxidant enzyme expression by PTU-induced hypothyroidism in cerebral cortex of postnatal rat brain,” Neurochemical Research, vol. 38, no. 1, pp. 42–49, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Jena and S. Bhanja, “Hypothyroidism alters antioxidant defence system in rat brainstem during postnatal development and adulthood,” Neurological Sciences, vol. 35, no. 8, pp. 1269–1274, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. Y.-S. Ho, Y. Xiong, W. Ma, A. Spector, and D. S. Ho, “Mice lacking catalase develop normally but show differential sensitivity to oxidant tissue injury,” The Journal of Biological Chemistry, vol. 279, no. 31, pp. 32804–32812, 2004. View at Publisher · View at Google Scholar · View at Scopus
  53. T. Pan, M. Zhong, X. Zhong, Y. Zhang, and D. Zhu, “Levothyroxine replacement therapy with vitamin E supplementation prevents oxidative stress and cognitive deficit in experimental hypothyroidism,” Endocrine, vol. 43, no. 2, pp. 434–439, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. G. Baskol, H. Atmaca, F. Tanriverdi, M. Baskol, D. Kocer, and F. Bayram, “Oxidative stress and enzymatic antioxidant status in patients with hypothyroidism before and after treatment,” Experimental and Clinical Endocrinology and Diabetes, vol. 115, no. 8, pp. 522–526, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Dasgupta, S. Das, and P. K. Sarkar, “Thyroid hormone promotes glutathione synthesis in astrocytes by up regulation of glutamate cysteine ligase through differential stimulation of its catalytic and modulator subunit mRNAs,” Free Radical Biology and Medicine, vol. 42, no. 5, pp. 617–626, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. A. Dasgupta, S. Das, and P. K. Sarkar, “Thyroid hormone stimulates γ-glutamyl transpeptidase in the developing rat cerebra and in astroglial cultures,” Journal of Neuroscience Research, vol. 82, no. 6, pp. 851–857, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. O. M. Ahmed, A. El-Gareib, A. El-Bakry, S. A. El-Tawab, and R. Ahmed, “Thyroid hormones states and brain development interactions,” International Journal of Developmental Neuroscience, vol. 26, pp. 147–209, 2008. View at Google Scholar
  58. S. Polvani, M. Tarocchi, and A. Galli, “PPARγ and oxidative stress: con(β) catenating NRF2 and FOXO,” PPAR Research, vol. 2012, Article ID 641087, 15 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. I. Villegas, A. R. Martín, W. Toma, and C. Alarcón De La Lastra, “Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, protects against gastric ischemia-reperfusion damage in rats: role of oxygen free radicals generation,” European Journal of Pharmacology, vol. 505, no. 1-3, pp. 195–203, 2004. View at Publisher · View at Google Scholar · View at Scopus
  60. G. Şener, A. Ö. Şehirli, N. Gedik, and G. A. Dülger, “Rosiglitazone, a PPAR-γ ligand, protects against burn-induced oxidative injury of remote organs,” Burns, vol. 33, no. 5, pp. 587–593, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. K. Chen, D. Li, X. Zhang, P. L. Hermonat, and J. L. Mehta, “Anoxia-reoxygenation stimulates collagen type-I and MMP-1 expression in cardiac fibroblasts: modulation by the PPAR-γ ligand pioglitazone,” Journal of Cardiovascular Pharmacology, vol. 44, no. 6, pp. 682–687, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. A. D. Dobrian, S. D. Schriver, A. A. Khraibi, and R. L. Prewitt, “Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity,” Hypertension, vol. 43, no. 1, pp. 48–56, 2004. View at Publisher · View at Google Scholar · View at Scopus
  63. E. Gray, M. Ginty, K. Kemp, N. Scolding, and A. Wilkins, “The PPAR-gamma agonist pioglitazone protects cortical neurons from inflammatory mediators via improvement in peroxisomal function,” Journal of Neuroinflammation, vol. 9, article 63, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. M. M. El-Naa, M. F. El-Refaei, W. A. Nasif, S. H. Abduljawad, A. I. El-Brairy, and M. Z. El-Readi, “In-vivo antioxidant and anti-inflammatory activity of rosiglitazone, a peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonists in animal model of bronchial asthma,” Journal of Pharmacy and Pharmacology, vol. 67, no. 10, pp. 1421–1430, 2015. View at Publisher · View at Google Scholar · View at Scopus
  65. A. P. Kudin, G. Debska-Vielhaber, and W. S. Kunz, “Characterization of superoxide production sites in isolated rat brain and skeletal muscle mitochondria,” Biomedicine and Pharmacotherapy, vol. 59, no. 4, pp. 163–168, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. B. Brunmair, K. Staniek, F. Gras et al., “Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?” Diabetes, vol. 53, no. 4, pp. 1052–1059, 2004. View at Publisher · View at Google Scholar · View at Scopus
  67. C. Dello Russo, V. Gavrilyuk, G. Weinberg et al., “Peroxisome proliferator-activated receptor γ thiazolidinedione agonists increase glucose metabolism in astrocytes,” Journal of Biological Chemistry, vol. 278, no. 8, pp. 5828–5836, 2003. View at Publisher · View at Google Scholar · View at Scopus
  68. J. R. Colca, W. G. McDonald, D. J. Waldon et al., “Identification of a novel mitochondrial protein (‘mitoNEET’) cross-linked specifically by a thiazolidinedione photoprobe,” American Journal of Physiology-Endocrinology and Metabolism, vol. 286, no. 2, pp. E252–E260, 2004. View at Google Scholar · View at Scopus
  69. A. S. Divakaruni, S. E. Wiley, G. W. Rogers et al., “Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 14, pp. 5422–5427, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. P.-E. Chabrier, C. Demerlé-Pallardy, and M. Auguet, “Nitric oxide synthases: targets for therapeutic strategies in neurological diseases,” Cellular and Molecular Life Sciences, vol. 55, no. 8, pp. 1029–1035, 1999. View at Publisher · View at Google Scholar · View at Scopus
  71. R. R. Jonnala and J. J. Buccafusco, “Inhibition of nerve growth factor signaling by peroxynitrite,” Journal of Neuroscience Research, vol. 63, no. 1, pp. 27–34, 2001. View at Google Scholar · View at Scopus
  72. G. A. Böhme, C. Bon, J.-M. Stutzmann, A. Doble, and J.-C. Blanchard, “Possible involvement of nitric oxide in long-term potentiation,” European Journal of Pharmacology, vol. 199, no. 3, pp. 379–381, 1991. View at Publisher · View at Google Scholar · View at Scopus
  73. K. Shibuki and D. Okada, “Endogenous nitric oxide release required for long-term synaptic depression in the cerebellum,” Nature, vol. 349, no. 6307, pp. 326–328, 1991. View at Publisher · View at Google Scholar · View at Scopus
  74. Y. Ueta, A. Levy, H. S. Chowdrey, and S. L. Lightman, “Hypothalamic nitric oxide synthase gene expression is regulated by thyroid hormones,” Endocrinology, vol. 136, no. 10, pp. 4182–4187, 1995. View at Google Scholar · View at Scopus
  75. E. Cano-Europa, F. Pérez-Severiano, P. Vergara et al., “Hypothyroidism induces selective oxidative stress in amygdala and hippocampus of rat,” Metabolic Brain Disease, vol. 23, no. 3, pp. 275–287, 2008. View at Publisher · View at Google Scholar · View at Scopus
  76. R. A. Sinha, A. Pathak, V. Mohan, S. Bandyopadhyay, L. Rastogi, and M. M. Godbole, “Maternal thyroid hormone: a strong repressor of neuronal nitric oxide synthase in rat embryonic neocortex,” Endocrinology, vol. 149, no. 9, pp. 4396–4401, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. R. Radi, A. Cassina, R. Hodara, C. Quijano, and L. Castro, “Peroxynitrite reactions and formation in mitochondria,” Free Radical Biology and Medicine, vol. 33, no. 11, pp. 1451–1464, 2002. View at Publisher · View at Google Scholar · View at Scopus
  78. M. C. Franco, V. G. Antico Arciuch, J. G. Peralta et al., “Hypothyroid phenotype is contributed by mitochondrial complex I inactivation due to translocated neuronal nitric-oxide synthase,” Journal of Biological Chemistry, vol. 281, no. 8, pp. 4779–4786, 2006. View at Publisher · View at Google Scholar · View at Scopus